Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $234.5 million.

  • Foghorn Therapeutics' Non-Current Deffered Revenue fell 22.62% to $193.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.1 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $234.5 million for FY2024, which is 12.55% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Deffered Revenue of $234.5 million as of FY2024, which was down 12.55% from $268.1 million recorded in FY2023.
  • Foghorn Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $322.7 million during FY2021, with a 5-year trough of $12.5 million in FY2020.
  • For the 3-year period, Foghorn Therapeutics' Non-Current Deffered Revenue averaged around $268.9 million, with its median value being $268.1 million (2023).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 2,472.37% in 2021, then declined by 12.55% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $12.5 million in 2020, then soared by 2,472.37% to $322.7 million in 2021, then decreased by 5.80% to $304.0 million in 2022, then declined by 11.80% to $268.1 million in 2023, then dropped by 12.55% to $234.5 million in 2024.